A Study of Ocrelizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA)

Summary

This study is in two parts and will evaluate the safety, tolerability and efficacy of escalating single intravenous (IV) doses of ocrelizumab compared with placebo in combination with methotrexate in participants with moderate to severe RA. Part 1 is the dose-escalation study, at one of the following dose levels of ocrelizumab \[400, 1000, 1500, and 2000 milligrams (mg)\]. In Part 2, participants will be randomized to explore tolerability and efficacy of doses which have been shown to be tolerated in Part 1.

Timeline

Start

2005-10

Primary completion

2013-02

Completion

2013-02

Drugs

Indications